Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
+0.25 (0.29%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 84.48 - 85.59
52 week 65.76 - 90.50
Open 84.81
Vol / Avg. 0.00/4.92M
Mkt cap 68.32B
P/E 54.31
Div/yield     -
EPS 1.57
Shares 800.83M
Beta 1.15
Inst. own 82%
Jul 24, 2014
Q2 2014 Celgene Corp. Earnings Release - 9:30AM EDT - Add to calendar
Jul 24, 2014
Q2 2014 Celgene Corp Earnings Call - 9:00AM EDT - Add to calendar
Jun 18, 2014
Celgene Corp. Annual Shareholder Meeting
Jun 11, 2014
Celgene Corp. at William Blair & Company LLC Growth Stock Conference
Jun 11, 2014
Celgene Corp. at Goldman Sachs Healthcare Conference
Jun 4, 2014
Celgene Corp. at Jefferies Global Healthcare Conference
May 29, 2014
Celgene Corp. at Sanford C Bernstein Strategic Decisions Conference
May 19, 2014
Celgene Corp. at UBS Global Healthcare Conference
May 13, 2014
Celgene Corp. at Bank of America Merrill Lynch Health Care Conference
May 7, 2014
Celgene Corp. at Robert W. Baird & Co. Inc Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 16.17% 22.33%
Operating margin 20.91% 27.86%
EBITD margin - 36.25%
Return on average assets 8.60% 11.55%
Return on average equity 22.27% 25.70%
Employees 5,100 -
CDP Score - 80 C


SUMMIT, NJ 07901
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Richard W. Barker OBE Independent Director
Age: 65
Bio & Compensation  - Reuters